TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31431084

Group type: EXPERIMENTAL
Intervention: Combination of patient characteristics, trauma characteristics, and knee complaints
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Combination of patient characteristics, trauma characteristics, knee complaints, and MR findings
Number of subjects: 250
Study: 28607125

Group type: EXPERIMENTAL
Intervention: Enalapril and folic acid (10 mg enalapril and 0.8 mg folic acid)
Number of subjects: 13071

Group type: COMPARATOR
Intervention: Enalapril (10 mg)
Number of subjects: 13071
Study: 26009787

Group type: EXPERIMENTAL
Intervention: PE + NAL
Number of subjects: 159

Group type: COMPARATOR
Intervention: PE + PBO
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: SC + NAL
Number of subjects: 159

Group type: COMPARATOR
Intervention: SC + PBO
Number of subjects: 159
Study: 23727883

Group type: EXPERIMENTAL
Intervention: High-low-frequency sequence paired with leftward apparent visual motion during adaptation phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-low-frequency sequence paired with rightward apparent visual motion during adaptation phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged exposure to audio-visual stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to visual field
Number of subjects: 0
Study: 22299414

Group type: EXPERIMENTAL
Intervention: Model 2 (phone call reminder) in MDR-TB group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Model 1 (conventional DOTS) in MDR-TB group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model 2 (phone call reminder) in non-MDR-TB group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Model 1 (conventional DOTS) in non-MDR-TB group
Number of subjects: 0
Study: 20035593

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 16982277

Group type: EXPERIMENTAL
Intervention: Epiphany + gutta‐percha
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: AH Plus + gutta‐percha
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: AH Plus + Resilon
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Epiphany + Resilon
Number of subjects: 70
Study: 15107971

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg
Number of subjects: 588

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g
Number of subjects: 588
Study: 11098023

Group type: EXPERIMENTAL
Intervention: Ofloxacin or doxycycline for 14 consecutive days per month for 3 months (PR: n = 40; PV: n = 20; PVE: n = 25)
Number of subjects: 122

Group type: COMPARATOR
Intervention: No treatment (PR: n = 12; PV: n = 12; PVE: n = 13)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ofloxacin or doxycycline
Number of subjects: 122

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 122
Study: 9195695

Group type: EXPERIMENTAL
Intervention: Conventional red cell salvage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red cell salvage with continuous processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salvage by haemofiltration using recirculation through a 30,000‐Da filter
Number of subjects: 0

Group type: COMPARATOR
Intervention: All three methods
Number of subjects: 0
Study: 1442658

Group type: EXPERIMENTAL
Intervention: Guar gum (10 grams, three times a day for 6 weeks)
Number of subjects: 25
Study: 3974174

Group type: EXPERIMENTAL
Intervention: Nimodipine (40, 60, or 80 mg orally)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg orally)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nimodipine i.v. (in 6 patients with vasospasm)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 42
Study: 3544028

Group type: EXPERIMENTAL
Intervention: diatrizoate sodium meglumine
Number of subjects: 25

Group type: COMPARATOR
Intervention: ioxaglate sodium meglumine
Number of subjects: 25
Study: 29665087

Group type: EXPERIMENTAL
Intervention: Vitamin D 1000 IU/d
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Vitamin D 400 IU/d
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 26803455

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 41
Study: 23929827

Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Exercise therapy (ET) + manual therapy (MT)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Baseline predictors for ET at 9 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Baseline predictors for ET at 18 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Prognostic accuracy for predictors at 9 weeks
Number of subjects: 131
Study: 24330776

Group type: EXPERIMENTAL
Intervention: Guided placement of ventricular catheters using a smartphone assisted guiding tool
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard freehand technique of ventricular catheter application
Number of subjects: 144
Study: 20533796

Group type: EXPERIMENTAL
Intervention: Value-neutral information about genomic science (short film)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 0
Study: 18788025

Group type: EXPERIMENTAL
Intervention: Square puzzle session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20% completion session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facile task trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difficult task trials
Number of subjects: 0
Study: 16845582

Group type: EXPERIMENTAL
Intervention: Good apology
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Pseudo-apology
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: No apology
Number of subjects: 184

Group type: COMPARATOR
Intervention: Non-harassed control
Number of subjects: 184
Study: 12790293

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (220 mg) once per day for one month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saccharose)
Number of subjects: 40
Study: 10666180

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg per hour TFPI after a bolus of 0.0125 mg/kg (low-dose group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg per hour TFPI after a bolus of 0.05 mg/kg (high-dose group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8877680

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine (oral formulation)
Number of subjects: 16
Study: 1793783

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily for one week
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6571974

Group type: EXPERIMENTAL
Intervention: naproxen sodium (275 mg, 2 tablets at first sign of menses, followed by one tablet 4 times daily for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 12
Study: 31204597

Group type: EXPERIMENTAL
Intervention: Active balanced sitting chair (ST)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stability ball (SB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard chair (SC)
Number of subjects: 20
Study: 30278530

Group type: EXPERIMENTAL
Intervention: Periocular triamcinolone acetonide (TA) injection
Number of subjects: 22

Group type: COMPARATOR
Intervention: Anti-VEGF intravitreous injection
Number of subjects: 22
Study: 25452018

Group type: EXPERIMENTAL
Intervention: Interspinous process devices (IPD)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Bony decompression
Number of subjects: 159
Study: 24682463

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate at 1.4 mg/m² as 2- to 5-minute intravenous infusions on days 1 and 8 of a 21-day cycle
Number of subjects: 827
Study: 22610930

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/d)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Amoxicillin (1000 mg/d)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo matching doxycycline
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Doxycycline and Amoxicillin
Number of subjects: 162
Study: 20562608

Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (n = 58)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 108
Study: 18626047

Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole, 800 mg daily for 2 weeks
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole, 800 mg daily
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 16003538

Group type: EXPERIMENTAL
Intervention: 12-month resistance training (TRN), training three times a week
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 12-month resistance training (TRN)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 13
Study: 11115415

Group type: EXPERIMENTAL
Intervention: Phenylephrine test (Phe-BRS)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre (Ov-VM-BRS)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre (IV-VM-BRS)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dichotomized Ov-VM-BRS
Number of subjects: 104
Study: 9863081

Group type: EXPERIMENTAL
Intervention: Xuefuzhuyu Pill (XFZYP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 12
Study: 8145982

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 59

Group type: COMPARATOR
Intervention: 2% carteolol
Number of subjects: 59
Study: 2462025

Group type: EXPERIMENTAL
Intervention: Involved field irradiation (IF) plus six cycles of vinblastine, bleomycin, and methotrexate (VBM)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Subtotal or total lymphoid irradiation (STLI/TLI) alone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Involved field irradiation (IF) alone (previous results)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Involved field irradiation (IF) plus nitrogen mustard, vincristine, procarbazine, +/‐ prednisone (MOP[P]) chemotherapy (previous results)
Number of subjects: 67
Study: 30991110

Group type: EXPERIMENTAL
Intervention: Financial incentives for weight management programs (Healthy Choices Healthy Changes: HCHC)
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation interventions (Breathe Well Live Well: BWLW)
Number of subjects: 2009

Group type: COMPARATOR
Intervention: No financial incentives for weight management programs (Healthy Choices Healthy Changes: HCHC)
Number of subjects: 2009

Group type: COMPARATOR
Intervention: No financial incentives for smoking cessation interventions (Breathe Well Live Well: BWLW)
Number of subjects: 2009
Study: 28424897

Group type: EXPERIMENTAL
Intervention: Electronic Case History Tool (e‐HiT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paper-based version (PBV)
Number of subjects: 40
Study: 25751133

Group type: EXPERIMENTAL
Intervention: Diastat activated after 4 weeks (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diastat activated after 12 weeks (Group 2)
Number of subjects: 30
Study: 24082784

Group type: EXPERIMENTAL
Intervention: mIoT management
Number of subjects: 600

Group type: COMPARATOR
Intervention: Routine follow-up
Number of subjects: 600
Study: 21390262

Group type: EXPERIMENTAL
Intervention: Counseling (three counseling sessions around HAART initiation)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Alarm (pocket electronic pill reminder carried for 6 months)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Counseling plus alarm
Number of subjects: 400

Group type: COMPARATOR
Intervention: Neither counseling nor alarm
Number of subjects: 400
Study: 19395227

Group type: EXPERIMENTAL
Intervention: Caregivers with limited health literacy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Caregivers with adequate health literacy
Number of subjects: 110
Study: 17669080

Group type: EXPERIMENTAL
Intervention: Closed Loop Stimulation (CLS) pacing mode
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accelerometer pacing mode
Number of subjects: 0
Study: 15509084

Group type: EXPERIMENTAL
Intervention: Whitening toothpaste (natural calcium carbonate/perlite)
Number of subjects: 600

Group type: COMPARATOR
Intervention: DCPD toothpaste (dicalcium phosphate dihydrate)
Number of subjects: 600

Group type: COMPARATOR
Intervention: PCC toothpaste (precipitated calcium carbonate)
Number of subjects: 600
Study: 11567200

Group type: EXPERIMENTAL
Intervention: Pilot group (promotion programmes)
Number of subjects: 7382

Group type: COMPARATOR
Intervention: Control group (no promotion programmes)
Number of subjects: 7382

Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 7382
Study: 9624074

Group type: EXPERIMENTAL
Intervention: Hospital at home
Number of subjects: 241

Group type: COMPARATOR
Intervention: Acute hospital care
Number of subjects: 241
Study: 7883291

Group type: EXPERIMENTAL
Intervention: Zinc treated group (Gp B) - 45 mg elemental zinc, single daily post lunch dose
Number of subjects: 162

Group type: COMPARATOR
Intervention: Untreated control group (Gp A)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Zinc treated group (Gp B)
Number of subjects: 162
Study: 3123538

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium therapy (active)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo theophylline (control)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Theophylline therapy (prior treatment)
Number of subjects: 29
Study: 30212848

Group type: EXPERIMENTAL
Intervention: Multi-player exergames
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single-player exergames
Number of subjects: 72
Study: 27057600

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) program, 24 weeks, 3 times per week
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 113
Study: 25287282

Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise twice a week during gestational weeks 14‐25
Number of subjects: 92

Group type: COMPARATOR
Intervention: Generalized exercise recommendation, home‐based training program, and telephone follow up
Number of subjects: 92
Study: 23903454

Group type: EXPERIMENTAL
Intervention: Wound edge protection device
Number of subjects: 760

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 760
Study: 21784350

Group type: EXPERIMENTAL
Intervention: Semagacestat (γ‐secretase inhibitor)
Number of subjects: 2762

Group type: EXPERIMENTAL
Intervention: Solanezumab (anti-Aβ monoclonal antibody)
Number of subjects: 2762

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2762
Study: 19493297

Group type: EXPERIMENTAL
Intervention: IST(R) appliance
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: TAP() appliance
Number of subjects: 103

Group type: COMPARATOR
Intervention: Both appliances
Number of subjects: 103
Study: 16676776

Group type: EXPERIMENTAL
Intervention: Tiagabine 8 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 15294387

Group type: EXPERIMENTAL
Intervention: Positive feedback condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative feedback condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (yoked control partner)
Number of subjects: 0
Study: 11375848

Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g IV)
Number of subjects: 164
Study: 7488285

Group type: COMPARATOR
Intervention: Prednisone plus cyclophosphamide (intravenous bolus)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Prednisone plus cyclophosphamide (intravenous bolus) plus plasma exchanges
Number of subjects: 62
Study: 2096413

Group type: EXPERIMENTAL
Intervention: 100 micrograms selenium daily for 5 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 356311

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study: 31482307

Group type: EXPERIMENTAL
Intervention: L19IL2 in combination with dacarbazine (DTIC; 1000 mg/m2 on day 1 of 21-day cycles)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC; 1000 mg/m2 on day 1 of 21-day cycles)
Number of subjects: 69
Study: 27575306

Group type: EXPERIMENTAL
Intervention: Elective EVAR
Number of subjects: 1231

Group type: COMPARATOR
Intervention: Men
Number of subjects: 1231
Study: 26161612

Group type: EXPERIMENTAL
Intervention: Midazolam-Ketamine (MK)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Midazolam (M)
Number of subjects: 13
Study: 25384996

Group type: EXPERIMENTAL
Intervention: Respiratory-gated strategy with 4-dimensional CT treatment planning
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ungated strategy with 1× PCR
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ungated strategy with 4× PCR
Number of subjects: 14
Study: 24654220

Group type: EXPERIMENTAL
Intervention: Opioid dose
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Average pain intensity
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Pain right now
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Worst pain intensity
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Pain at its least
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Pain relief
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Pain interference
Number of subjects: 2201
Study: 19858764

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Estrogen + progestin therapy
Number of subjects: 2380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2380
Study: 17345052

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (maximum 100 units)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study: 16262020

Group type: EXPERIMENTAL
Intervention: Metronidazole (200 mg 3 times daily for 7 days) and cephalexin (500 mg twice daily for 5 days)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no antimicrobials)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Metronidazole and cephalexin
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Stunted mothers (<25th centile or 146.4 cm)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Low maternal body mass index (<25th centile or 18)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: High body mass index (>75th centile or 21.2)
Number of subjects: 224
Study: 11923647

Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10221237

Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C and 800 mg vitamin E (n = 15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Identical placebo capsules (n = 16)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prolonged abstinence time
Number of subjects: 31
Study: 8549178

Group type: EXPERIMENTAL
Intervention: Handheld portable spirometer
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional volume displacement spirometer
Number of subjects: 75
Study: 1702048

Group type: EXPERIMENTAL
Intervention: Insulin and glucagon (treatment group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 38
Study: 6342955

Group type: EXPERIMENTAL
Intervention: 40 mg tilcotil (Ro12-0068) once daily for 2 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: 900 mg enteric-coated aspirin 4 times daily for 2 weeks
Number of subjects: 8
Study: 31710306

Group type: EXPERIMENTAL
Intervention: Oral Health Text messages (OHT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Child Wellness Text messages (CWT)
Number of subjects: 55
Study: 26607495

Group type: EXPERIMENTAL
Intervention: Isotonic 0.9% sodium chloride
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Hypertonic 3% sodium chloride
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: WARM respiratory distress score
Number of subjects: 133
Study: 24785600

Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation
Number of subjects: 121

Group type: COMPARATOR
Intervention: Electrosurgical resection
Number of subjects: 121
Study: 22748729

Group type: EXPERIMENTAL
Intervention: Cognitive intervention program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 19486267

Group type: EXPERIMENTAL
Intervention: Intralesional BCG-PSN injection (0.5 ml every other day for 2 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (10 mg every week for 2 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intralesional BCG-PSN injection
Number of subjects: 56

Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 56
Study: 17300479

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention for diabetes management
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 116
Study: 15149248

Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT) with nonassociated, neutral categories differing in salience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT) with manipulated salience asymmetries while holding associations constant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT) with manipulated valent associations while holding salience asymmetries constant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual search task to assess salience asymmetries
Number of subjects: 0
Study: 11606340

Group type: EXPERIMENTAL
Intervention: IM droperidol 0.1 mg x kg(‐1) 30 min before anesthesia
Number of subjects: 23

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 23
Study: 9539198

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (stress reduction)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (energy intake reduction)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dietary advice alone
Number of subjects: 60
Study: 9116924

Group type: EXPERIMENTAL
Intervention: losartan 50 mg
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: losartan 50 mg titrated to 100 mg
Number of subjects: 366

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 366